Sign Up to like & get
recommendations!
0
Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01087-z
Abstract: Tagraxofusp (tagraxofusp-erzs) [Elzonrisā¢] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm…
read more here.
Keywords:
treatment;
tagraxofusp first;
tagraxofusp;
global approval ... See more keywords